Indivior Pharmaceuticals, Inc. (INDV) Stock

About Indivior Pharmaceuticals, Inc.

Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market. Established on September 26, 2014, its corporate headquarters are located in North Chesterfield, Virginia.

Indivior Pharmaceuticals, Inc. (INDV) stock trades at $34.47 with a market capitalization of $4.30B. The stock is valued at a price-to-earnings (P/E) ratio of 12.72, a negative price-to-book of -21.77, reflecting negative shareholders' equity, price-to-sales of 3.38. Over the past 52 weeks the stock has ranged between $24.03 and $42.81, and currently trades 19.5% below its 52-week high. It pays a dividend yielding 23.80%.

On profitability, Indivior Pharmaceuticals, Inc. generates a return on equity (ROE) of -216.13% (not meaningful, as shareholders' equity is negative), return on capital employed of 91.38%, an operating margin of 33.31%, a net profit margin of 26.65%.

Official website: www.indivior.com

Indivior Pharmaceuticals, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Indivior Pharmaceuticals, Inc. reported revenue of $969.0M rising to $1.2B, a change of +27.9% across 10 years. Compounded, revenue has grown 13.9% a year over five years, 11.2% over three, 4.3% over the last twelve months. Net profit rose to $210.0M.

Operating margin went from 34.9% in 2016 to 21.4% in 2025, a fall of 13.5 percentage points. The most recent net margin is 26.65%. On a trailing twelve-month basis to Jun '26, revenue is $1.3B and net profit $355.0M.

Borrowings fell from $535.0M to $351.0M, cash from operations was $-27.0M in the latest year, positive in 6 of the last 10.

Return on equity has averaged -26.5% over five years, and was -214.3% in the most recent year.

The share price itself has compounded at 27.5% a year over five years, 18.9% over three, 174.4% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Indivior Pharmaceuticals, Inc. (INDV) — frequently asked questions